EUVIMEDEUVIMED entdecken
Crossref

Characterization of bridging therapies in clinical trials leading to FDA approval of CAR ‐T cell therapies

Victoria Kaestner, Alyson Haslam iD, Vinay Prasad iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Victoria Kaestner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Arnold Ventures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the time of chimeric antigen receptor T‐cell (CAR‐T) manufacturing, bridging therapy is often used to control disease. Because it often involves systemic treatment, the bridging therapies can induce responses and/or adverse events. We sought to assess bridging therapies used in CAR‐T trials in a cross‐sectional study. We reviewed FDA drug labels and peer‐reviewed registration trial reports (including supplemental data) to evaluate the characteristics of bridging therapy used in trials testing CAR‐T therapies. We looked at which bridging therapies were used, whether multiple therapies were combined, the response rates, and the reported adverse events associated with bridging therapy. Of the 11 studies testing CAR‐T therapies, 10 reported the bridging therapies that were used in the study. Of those that reported the types of bridging therapies ( n = 10), the most commonly used bridging therapy was dexamethasone (10/10, 100%), rituximab (6/10, 60%), gemcitabine (5/10, 50%), and etoposide (5/10, 50%). Of the trials, one of 11 (9%) clearly reported whether patients had responses to bridging therapy, six of 11 (55%) vaguely reported responses, and four of 11 (36%) trials did not report or mention any response information regarding bridging therapy. Although patients are often refractory to first‐line therapies, which share considerable overlap with bridging therapies, these therapies may induce responses. Despite this possibility, the reporting of bridging therapy combinations and their subsequent response rates and adverse event rates are highly variable. These findings highlight the need for greater transparency in the reporting of bridging therapy to more reliably assess the efficacy of CAR‐T therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasmsHumansUnited StatesUnited States Food and Drug AdministrationClinical Trials as TopicCross-Sectional StudiesDrug ApprovalDexamethasoneGemcitabineRituximabEtoposideDeoxycytidineReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR‐Tadverse eventsbridging therapyresponse

Substanzen

Receptors, Chimeric AntigenDexamethasoneGemcitabineRituximabEtoposideDeoxycytidineReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Alyson Haslam, Vinay Prasad

Förderung

  • Arnold Ventures

Zitieren

APA

Kaestner, V., Haslam, A., & Prasad, V. (2025). Characterization of bridging therapies in clinical trials leading to FDA approval of CAR ‐T cell therapies. International Journal of Cancer. https://doi.org/10.1002/ijc.35473

Vancouver

Kaestner V, Haslam A, Prasad V. Characterization of bridging therapies in clinical trials leading to FDA approval of CAR ‐T cell therapies. International Journal of Cancer. 2025. doi:10.1002/ijc.35473

BibTeX
@article{Kaestner2025,
  author = {Kaestner, Victoria and Haslam, Alyson and Prasad, Vinay},
  title = {Characterization of bridging therapies in clinical trials leading to FDA approval of CAR ‐T cell therapies},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35473}
}
Kostenlos starten →